Ivax Paxene Second-Line Indication Reflects Comparison To Doxil/DaunoXome
Executive Summary
The second-line Kaposi's sarcoma indication for Ivax' paclitaxel brand Paxene in the European Union appears to be based on a balancing of potentially superior response rates against a potentially greater risk of neutropenia, the European Public Assessment Report indicates.